Spyre Therapeutics, Inc. Logo

Spyre Therapeutics, Inc.

Engineering advanced antibody therapies for IBD and other immune diseases.

SYRE | US

Overview

Corporate Details

ISIN(s):
US00773J1034 (+1 more)
LEI:
Country:
United States of America
Address:
221 CRESCENT STREET, 2453 WALTHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation treatments for inflammatory bowel disease (IBD) and other immune-mediated diseases. The company's approach involves engineering advanced antibodies for prolonged activity in the body, which are formulated for delivery as monotherapies or combination therapies. Spyre's pipeline targets validated mechanisms to treat various gastrointestinal and rheumatic conditions, with the goal of providing patients with treatment options that offer enhanced efficacy and convenience.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Spyre Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Spyre Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Spyre Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.